Every person is unique.
Every person’s cancer is unique.
Every cancer patient’s treatment must be unique.


Who we are

Linq Labs is an innovative niche laboratory which is a unit of Jehangir Clinical Development Centre (JCDC) (www.jcdc.co.in). JCDC is an award winning and highly respected clinical research centre in India.

Why choose us?

Linq Labs has developed a novel methodology in the field of personalized medicine for cancer treatment. Unfortunately, most cancer specialists today guess which therapy will work based on standard protocols and their experience. Linq Labs helps to eliminate that guesswork. Linq Labs has devised, developed and validated a ChemoSensitivity assay or laboratory test for individualizing patient therapy. ChemoSensitivity assay determines how effective specific chemotherapy agents are against an individual patient's cancer cells. This kind of testing can assist in individualizing cancer therapy by providing information about the likely response of an individual patient's tumor to proposed therapy.


Truly personalized treatment

Our ChemoSensitivity assay identifies the most effective chemotherapy regimen that will kill a person’s cancer cells. Once the tumour sample is collected, we would then measure cell death in the laboratory. Regardless of the specific pathway, the end result (the death of the tumor cell) provides the needed insight to allow for improved drug selection.

Our Vision

We are passionate about transforming patient’s lives. We strive to improve out comes in cancer patients to make a difference. We commit to high quality diagnostics at affordable prices.


Sir. Cowasji Jehangir Baronet, Chairman

Sir Cowasji Jehangir Bt., is the chairman and a trustee of Jehangir Hospital and JCDC. He has a wealth of experience of leading from the front and is on the board of directors in various other public and private companies. Sir Jehangir is a true philanthropist and is involved in the management of charitable trusts for social good viz. Jehangir Art Gallery, Sir Cowasji Jehangir High School, Sir Cowasji Jehangir Charitable Trust, Hirabai Cowasji Charitable Trust and the Parsi Public School..

Dr. Uma Divate, MD.

Dr. Divate has over 40 years of clinical experience and has been the co Founder and Director of JCDC. She is also a Consultant Physician at Jehangir Hospital. An enthusiastic researcher, she has over 30 publications to her name and has made presentations at more than 150 conferences. A firm believer in advancing the frontiers of science through research, Dr. Divate goes to great lengths to help as many needy patients as is possible through research and is a true humanitarian.

Mr. Pathik Divate, CEO

Pathik brings his youthful energy and dynamism along with fifteen years of experience in three industries and across six countries. Pathik is a Chartered Accountant and an MBA from Thunderbird, The Garvin School in USA. He started his career at Deloitte in Auditing and consulting. Thereafter, he moved to the outsourcing industry where he worked in India and the UK. After his MBA he worked with Pfizer Inc. in New York. He moved back to India in 2007 and co-founded JCDC, which is a highly respected and acclaimed research centre in India and abroad.

Scientific Advisory Board

Dr. Mandar Kulkarni, PhD.

Dr. Mandar Kulkarni is on the Scientific Advisory Board of Linq Labs. He currently is the Chief Technology Officer (CTO) of Cancer Genetics, India, based in Hyderabad. Dr. Mandar has over five years of experience in both clinical and genomic development . Prior to this Dr. Mandar was the Head of molecular biology and genomics at Sandor Lifesciences, He was also a senior scientist at M/Z Diagnostics where he developed and clinically validated a diagnostic assay for rapid detection of multi-drug resistant bacterial infections.
Dr. Mandar received his Bachelor of Science degree from Pune University and the University of Wisconsin and earned a doctorate degree from Purdue University. He completed his postdoctoral training at Yale School of Medicine.

Dr. Rajesh Savkur, PhD

Dr. Rajesh has a PhD in biochemistry from University of Mississippi Medical Center. He has over 15 years experience in pharmacology and genetics in the pharmaceutical industry
Prior to this, Dr. Rajesh worked at Eli Lilly and Company and PTC Therapeutics, and has led drug discovery efforts against cardiovascular-metabolic, neuromuscular genetic, and inflammatory dermatological diseases. He is a member of the American Diabetes Association and Muscular Dystrophy Association, and serves as a reviewer for manuscripts submitted to journals.


5th Floor, Sohrab Hall ,32, Sasoon Road, Pune-411001